Trilogy Capital’s Neurocrine Biosciences NBIX Stock Holding History

Trilogy Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-43	Closed	-$5K	–	415
2018 Q3	$5K	Buy	+43	New	+$4.88K	﹤0.01%	403

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Trilogy Capital's NBIX Position: Q4 2018 in Review

Trilogy Capital sold out of Neurocrine Biosciences (NBIX) in Q4 2018, closing a stake of 43 shares — an estimated $5K sold.

Trilogy Capital first reported a position in NBIX in Q3 2018 and held it in 1 quarter. The position peaked at $5K in Q3 2018. 330 funds tracked by Wall St. Rank hold NBIX as of Q4 2018.

Trilogy Capital reported no remaining Neurocrine Biosciences position as of Q4 2018 after selling out during the quarter.
Trilogy Capital sold 43 Neurocrine Biosciences shares in Q4 2018, an estimated $5K.
Trilogy Capital first reported a position in Neurocrine Biosciences in Q3 2018 and held it in 1 quarter.
Trilogy Capital's Neurocrine Biosciences position peaked at $5K in Q3 2018.
330 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2018.

Based on Trilogy Capital's 13F filing for Q4 2018, filed 15 Jan 2019.